Fig. 2: Schematic representation of azacitidine and decitabine uptake and metabolism. | Leukemia

Fig. 2: Schematic representation of azacitidine and decitabine uptake and metabolism.

From: Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies

Fig. 2

5-aza-U 5-aza-uridine, 5-aza-dU 5-aza-2´-deoxyuridine, CDP cytidine diphosphate, CMP cytidine monophosphate, hCNT human concentrative nucleoside transporter, hENT human equilibrative nucleoside transporter, NDPK nucleoside diphosphate kinase, NMPK nucleoside monophosphate kinase, RNR ribonucleotide reductase.

Back to article page